New opportunities for injecting therapy of type 2 diabetes mellitus

Abstract

Over the past decade, the number of people with type 2 diabetes mellitus (T2DM) has more than doubled globally. For 2040, it was estimated by the International Diabetes Federation that 642 million people will have diabetes. According to the Federal Register of Diabetes Mellitus as of January 01.2019, more than 4.5 million patients with diabetes are registered in Russia, of which 4,238,503 are people with type 2 diabetes. However, these data are incomplete, as problems with timely diagnosis and active detection of glucose metabolism disorders continue to exist. Due to late diagnosis of T2DM, high rates of glycemia in the onset of the disease, as well as pronounced decompensation in association with oral hypoglycemic drugs during a long course of the disease, require the transfer of patients to injection therapy. The head of Diabetic Foot Department of the Research Center for Endocrinology of the Ministry of Health of the Russian Federation, Dr. of Sci. (Med.), Professor Gagik Radikovich Galstyan talks about the therapeutic possibilities of modern combined injection therapy.Interview with Gagik Galstyan